MIAMI, FL -- (MARKET WIRE) -- March 09, 2007 -- DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or “the Company”) announced that it has formed an experienced consulting team which includes key oncologic and gastrointestinal opinion leaders and ex-FDA personnel to prepare for the upcoming Oncologic Drugs Advisory Committee (“ODAC”) meeting, scheduled for May 10, 2007 at 8AM EDT. The ODAC meeting will review the New Drug Application (“NDA”) for orBec® (oral beclomethasone dipropionate) for the treatment of gastrointestinal Graft-versus-Host disease (“GI GVHD”).
